Bernard Portevin

1,3-Diaryl-4,5,6,7-tetrahydro-2<i>H</i>-isoindole Derivatives:  A New Series of Potent and Selective COX-2 Inhibitors in Which a Sulfonyl Group Is Not a Structural Requisite

Bernard Portevin, Charles Tordjman, Philippe Pastoureau et al. · Journal of Medicinal Chemistry · 2000 · 124 citations · Full text

Pharmacotherapy, New Series, Heterocycle Chemistry +19

Stereoselective synthesis of a new perhydroindole derivative of chiral iminodiacid, a potent inhibitor of angiotensin converting enzyme

M. Vincent, G. REMOND, Bernard Portevin et al. · Tetrahedron Letters · 1982 · 93 citations

Medicinal Chemistry, Chiral Iminodiacid, Biochemistry +8

New Prolyl Endopeptidase Inhibitors:  <i>In Vitro</i> and <i>in Vivo</i> Activities of Azabicyclo[2.2.2]octane, Azabicyclo[2.2.1]heptane, and Perhydroindole Derivatives

Bernard Portevin, Alain Benoist, G. REMOND et al. · Journal of Medicinal Chemistry · 1996 · 90 citations · Full text

Inhibitory Activity, Medicinal Chemistry, Pharmaceutical Science +14

Configuration and preferential solid-state conformations of perindoprilat (S-9780). Comparison with the crystal structures of other ACE inhibitors and conclusions related to structure-activity relationships

Claudine Pascard, Jean Guilhem, M Lynch Vincent et al. · Journal of Medicinal Chemistry · 1991 · 43 citations · Full text

Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues

Jean‐Gilles Parmentier, Bernard Portevin, Roy M. Golsteyn et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 40 citations · Full text

Medicinal Chemistry, Derivative (Chemistry), Medicine +4